Figures & data
Figure 1. Patients included in our study. Abbreviations: mRCC, metastatic renal cell carcinoma; P/A, pembrolizumab/axitinib; TKI, tyrosine kinase inhibitor; CT, computed tomography.
![Figure 1. Patients included in our study. Abbreviations: mRCC, metastatic renal cell carcinoma; P/A, pembrolizumab/axitinib; TKI, tyrosine kinase inhibitor; CT, computed tomography.](/cms/asset/d5c1ab6c-742c-4e34-8321-2237064b92c4/tepm_a_2330422_f0001_oc.jpg)
Table 1. Baseline patients’ features in both experimental (immune-based combination) and control (TKI) groups as well as in overall population, along with p-value for association between categorical or continuous variables and the two groups.
Figure 2. PFS in patients in the control group, treated with a single-agent TKI. Patients were further divided in two groups: group 1 with high velocity volume reduction (HvVR) and group 2 with lower velocity volume reduction or increase (LvVR).
![Figure 2. PFS in patients in the control group, treated with a single-agent TKI. Patients were further divided in two groups: group 1 with high velocity volume reduction (HvVR) and group 2 with lower velocity volume reduction or increase (LvVR).](/cms/asset/e6450b62-8c75-4f4b-8b30-57fc980f56bc/tepm_a_2330422_f0002_b.gif)
Figure 3. PFS in patients in the immunotherapy group, treated with pembrolizumab plus axitinib. Patients were further divided in two groups: group 1 with high velocity volume reduction (HvVR) and group 2 with lower velocity volume reduction or increase (LvVR).
![Figure 3. PFS in patients in the immunotherapy group, treated with pembrolizumab plus axitinib. Patients were further divided in two groups: group 1 with high velocity volume reduction (HvVR) and group 2 with lower velocity volume reduction or increase (LvVR).](/cms/asset/f0fdcd5f-2868-49fe-a9c6-de699ce53cec/tepm_a_2330422_f0003_b.gif)
Figure 4. OS in patients in the control group, treated with a single-agent TKI. Patients were further divided in two groups: group 1 with high velocity volume reduction (HvVR) and group 2 with lower velocity volume reduction or increase (LvVR).
![Figure 4. OS in patients in the control group, treated with a single-agent TKI. Patients were further divided in two groups: group 1 with high velocity volume reduction (HvVR) and group 2 with lower velocity volume reduction or increase (LvVR).](/cms/asset/afa39740-8bda-4d6a-b7a1-c43430714087/tepm_a_2330422_f0004_b.gif)
Figure 5. OS in patients in the immunotherapy group, treated with pembrolizumab plus axitinib. Patients were further divided in two groups: group 1 with high velocity volume reduction (HvVR) and group 2 with lower velocity volume reduction or increase (LvVR).
![Figure 5. OS in patients in the immunotherapy group, treated with pembrolizumab plus axitinib. Patients were further divided in two groups: group 1 with high velocity volume reduction (HvVR) and group 2 with lower velocity volume reduction or increase (LvVR).](/cms/asset/be89ca79-9fe6-4a83-9294-90473dbdedd7/tepm_a_2330422_f0005_b.gif)
Table 2. Association between survival outcomes and TGR at each CT assessment from first-line therapy’s start in patients treated with immune-based combination, single-agent TKI and in the overall population.
Data availability statement
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.